Ascendis Pharma A/S Ordinary Share (ASND) is a publicly traded Healthcare sector company. As of May 21, 2026, ASND trades at $241.34 with a market cap of $14.68B and a P/E ratio of 0.00. ASND moved +1.47% today. Year to date, ASND is +13.23%; over the trailing twelve months it is +49.37%. Its 52-week range spans $118.03 to $250.74. Analyst consensus is strong buy with an average price target of $299.17. Rallies surfaces ASND's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ascendis Pharma slides after May 7 Q1 2026 results and business update: Ascendis Pharma reported Q1 2026 results and a business update on May 7, 2026, highlighting €247 million total revenue driven mainly by YORVIPATH (€197 million). Shares fell as investors digested the quarterly update and near-term commercial dynamics discussed alongside the release.
| Metric | Value |
|---|---|
| Price | $241.34 |
| Market Cap | $14.68B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $250.74 |
| 52-Week Low | $118.03 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
12 analysts cover ASND: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $299.17.